申请人:ABT Holding Company
公开号:US20140194411A1
公开(公告)日:2014-07-10
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds. These compounds are serotonin receptor (5-HT
2c
) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT
2c
) is desired (e.g. addiction, anxiety, depression, obesity, and others).
本发明一般涉及一系列化合物,含有这些化合物的药物组合物,以及将这些化合物和组合物用作治疗剂。更具体地,本发明的化合物是苯并咪唑化合物。这些化合物是血清素受体(5-HT2c)配体,对于治疗需要调节血清素受体(5-HT2c)活性的疾病、障碍和病况(例如成瘾、焦虑、抑郁、肥胖等)非常有用。